FDA's Off-Label Data Dissemination Study Criteria Too Strict, HIMA Says
This article was originally published in The Gray Sheet
Information derived from a peer-reviewed investigation published in a scientific or medical journal about a new or unapproved use of a medical device, drug or biologic should be considered "scientifically sound" and therefore eligible for dissemination by manufacturers, the Health Industry Manufacturers Association maintains in recent comments to FDA.
You may also be interested in...
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.